Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
Kosiborod MN, Windsor SL, Vardeny O, et al.
Lancet Diabetes Endocrinol. 2024;12(10):725-734.
Leggi


